Atara Biotherapeutics Stock Dips Below Key Moving Average

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) encountered a significant drop in its stock price, crossing below its fifty-day moving average during trading on January 13, 2024. The stock, which has a fifty-day moving average of $8.72, fell to a low of $4.68 before settling at $5.26 with a trading volume of 510,858 shares.

Analysts Adjust Price Targets

Several analysts have recently provided updated insights into Atara’s stock performance. Notably, the Canaccord Genuity Group reaffirmed a “hold” rating while slashing its price target from $25.00 to $6.00. This sentiment was echoed by New Street Research, which also set a $6.00 price target. Meanwhile, Weiss Ratings issued a “sell (d)” rating in a report dated December 29, 2023. Currently, one analyst rates the stock as a hold, while another assigns a sell rating, leading to a consensus rating of “Reduce” and a target price of $6.00, according to MarketBeat.com.

Insider Transactions and Hedge Fund Activity

In a notable insider transaction, major shareholder Innovation Ltd Panacea sold 80,554 shares on January 12, 2024, at an average price of $6.07, totaling approximately $488,962.78. Following this sale, the insider retains 1,324,446 shares valued at about $8,039,387.22, which reflects a 5.73% decrease in their holdings. The sale was reported in a legal filing with the U.S. Securities and Exchange Commission.

Hedge funds have also been active regarding their positions in Atara Biotherapeutics. Quadrature Capital Ltd raised its stake by 22.8% during the fourth quarter, now owning 20,321 shares valued at $368,000 after acquiring an additional 3,779 shares. Similarly, Bridgeway Capital Management LLC increased its holdings by 133.5% to 32,691 shares, valued at $591,000. Other firms, including Marshall Wace LLP and Renaissance Technologies LLC, also boosted their positions, with hedge funds and institutional investors collectively owning 70.90% of the stock.

Atara Biotherapeutics, headquartered in South San Francisco, California, is focused on the discovery, development, and commercialization of innovative T-cell immunotherapies. The company aims to transform the treatment landscape for cancer and autoimmune diseases, leveraging its proprietary allogeneic Epstein-Barr virus (EBV)-directed T-cell platform. Its lead product candidate, tabelecleucel, is currently in clinical development for treating EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.

As Atara Biotherapeutics navigates these developments, investors and analysts alike will be closely monitoring the company’s performance and strategic direction in the coming months.